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Abstract
Background: Endothelial permeability is involved in injury, inflammation, diabetes and cancer. It is partly regulated
by the thrombin-, histamine-, and VEGF-mediated myosin-light-chain (MLC) activation pathways. While these
pathways have been investigated, questions such as temporal effects and the dynamics of multi-mediator
regulation remain to be fully studied. Mathematical modeling of these pathways facilitates such studies. Based on
the published ordinary differential equation models of the pathway components, we developed an integrated
model of thrombin-, histamine-, and VEGF-mediated MLC activation pathways.
Results: Our model was validated against experimental data for calcium release and thrombin-, histamine-, and
VEGF-mediated MLC activation. The simulated effects of PAR-1, Rho GTPase, ROCK, VEGF and VEGFR2 over-
expression on MLC activation, and the collective modulation by thrombin and histamine are consistent with
experimental findings. Our model was used to predict enhanced MLC activation by CPI-17 over-expression and by
synergistic action of thrombin and VEGF at low mediator levels. These may have impact in endothelial permeability
and metastasis in cancer patients with blood coagulation.
Conclusion: Our model was validated against a number of experimental findings and the observed synergistic
effects of low concentrations of thrombin and histamine in mediating the activation of MLC. It can be used to
predict the effects of altered pathway components, collective actions of multiple mediators and the potential
impact to various diseases. Similar to the published models of other pathways, our model can potentially be used
to identify important disease genes through sensitivity analysis of signalling components.
Background
The endothelium is a semi-permeable barrier that regu-
lates the flux of liquid and solutes between the blood and
surrounding tissues. Endothelial permeability increases
paracellular leakage of plasma fluid and proteins to sur-
rounding tissues, and intravasation of tissue-released
contents to the blood in the development of multiple dis-
eases related to injury (such as edema, trauma, ischae-
mia-reperfusion injury, respiratory distress syndrome,
and thrombosis), inflammation (such as atherosclerosis
and sepsis), diabetes, and cancer [1-4]. The level of
endothelial permeability is regulated individually or in
combination by multiple mediators, particularly
thrombin, histamine, and vascular endothelial growth
factor (VEGF), under various disease conditions [4].
The proinflammatory and vasoactive factors thrombin,
generated in thrombosis and inflammatory diseases, and
histamine, produced in acute inflammatory responses to
trauma, burns, allergy, and infection, induce transient
endothelial permeability to link inflammation, tissue injury
and vascular leakage to cellular responses and symptoms
[5-7]. VEGF, released in diabetic retinopathy, I-R injury,
vasculogenesis, angiogenesis, and tumor development and
metastasis, causes endothelial permeability to enable extra-
vasation of fluids and solutes and intravasation of tumor
cells [8-10]. These three key mediators stimulate their
respective receptors on endothelial cells to individually
and collectively activate Ca
2+, Rho GTPase/ROCK, and
Myosin light chain kinase (MLCK) signalling pathways
that subsequently activate myosin light chain (MLC) to
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dissociation of cell-cell junctions, resulting in endothelial
hyper-permeability [4,11].
Significant progress has been made in understanding
the molecular mechanism and dynamics of the relevant
signalling events [4,7,9,11,12] and the roles of different
regulators [13,14]. Nonetheless, some puzzles still
remain to be elucidated. For instance, it is unclear what
contributes to the different temporal effects and perme-
ability recovery rates by histamine, thrombin, and VEGF
mediated signalling, given that they share similar signal-
ling cascades in triggering endothelial permeability.
Another question is how multiple mediators under cer-
tain complicated inflammatory conditions collectively
reduce the effectiveness of antagonizing agents directed
at individual mediator-mediated signalling [4].
As part of the efforts for solving these puzzles and for
quantitative and mechanistic study of the relevant sig-
nalling events, mathematical models have been
developed for analyzing the relevant signalling and regu-
lation processes [15-20]. In particular, ordinary differen-
tial equation (ODE) based mathematical models of
thrombin, Ca
2+-calmodulin (CaM), and Rho activation
have been developed for investigating the thrombin-
mediated activation of MLC [18], and Ca
2+-CaM,
MLCK and Myosin Light chain phosphatase (MYCP) on
MLC activation [15,16,21]. To enable more comprehen-
sive analysis of signalling in endothelial permeability,
there is a need to develop an expanded ODE model that
covers the signalling mediated by multiple mediators,
particularly thrombin, histamine and VEGF.
In this work, we developed a mathematical model that
integrates thrombin, histamine, and VEGF mediated sig-
nalling in endothelial permeability by extending the
published ODE models of the thrombin-mediated path-
way and Ca
2+-CaM and MLCK activation of MLC
[15,16,18,21]. The framework of our integrated mathe-
matical model is illustrated in Figure 1 and the detailed
Figure 1 Framework of integrated pathway simulation model of thrombin-, histamine-, and VEGF-mediated MLC activation.T h e
components in existing models are highlighted by red, blue, and red + blue + green background colour for models from reference 15, 16 and
18 respectively. The protein in the gray box represents output signalling. ROCK (f) and ROCK (o) refer to ROCK in folded and open conformation
respectively.
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thrombin-, histamine- and VEGF-mediated signalling
cascades are given in Additional File 1, Figure S1, S2
and S3 respectively. Detailed molecular interactions and
t h ec o r r e s p o n d i n gk i n e t i cd a t aw e r eo b t a i n e df r o mt h e
literature, including published simulation models
[15,16,18,21], which are summarized in Additional File
2. Our model was validated by evaluating whether the
time course of MLC activation by each individual med-
iator (thrombin, histamine, and VEGF) is in agreement
with published experimental and computational findings.
The sensitivity of our model with respect to parameters
was analyzed to evaluate its robustness. The validated
model was then used to study the modulation of other
pathway components by each individual mediator
(thrombin, histamine, and VEGF) [4,11] and the modu-
lation of MLC activation by combination of a pair of
key mediators thrombin and histamine [22,23]. Our
model was further used to predict the regulation of
MLC activation by PKC-potentiated inhibitory protein
of 17 kDa (CPI-17) over-expression and by combination
of thrombin and VEGF at low mediator levels. The
effects of the protein variation of key signalling compo-
nents protease-activated receptor-1 (PAR-1), VEGF,
VEGFR2, Rho GTPase, and ROCK on MLC activation
were also studied. Some of these components are signifi-
cantly elevated in different diseases and have been
explored as therapeutic targets for pharmacological
intervention of endothelial permeability and barrier
function in these diseases [20].
Thrombin-, Histamine-and VEGF-Mediated
Signalling Cascades in Endothelial Permeability
Thrombin mediated GPCR activation
Thrombin regulates endothelial permeability, inflamma-
tion and other events via activation of thrombin recep-
tors such as PAR-1 by proteolytically cleaving the N-
terminus of these receptors [24]. PAR-1 is the main
receptor in the regulation of endothelial permeability
(Additional File 1, Figure S1). It interacts with Gq to
increase the concentration of Ca
2+ and activate protein
kinase C, inositol 1, 4, 5-triphosphate and diacylglycerol
[25]. It is also linked to G12/13 [26] to activate the
small G-protein Rho [27].
VEGF mediated ERK activation
VEGF regulates angiogenesis, cancer and microvascular
permeability under various physiological and pathologi-
cal conditions by activating transmembrane tyrosine
kinase receptors VEGFR-2 and Flt-1, which promotes
mitogenic, chemotactic, and prosurvival signalling and
activates phospholipase C (PLC), intracellular Ca
2+,a n d
various protein kinase C (PKC) isoforms. In particular,
VEGF activates ERK-1/2 via the Raf-MEK-ERK cascade
[28]. Accumulative evidences suggest that ERK-MLCK-
meditated cytoskeletal responses contribute to VEGF-
elicited microvascular hyperpermeability. For instance,
MLCK has been found to contain multiple MAP kinase
consensus phosphorylation sites (P-x-S[29]-P) that can
be directly phosphorylated by MAP kinase [30], which is
supported by additional experimental evidence indicat-
ing MLCK as a substrate for MAP kinase [31].
Histamine, VEGF mediated NO activation
Cytosolic Ca
2+ elevation is a typical initial response of
endothelial cells to hormonal and chemical signal and to
changes in physical parameters, and many endothelial
functions are dependent on changes in Ca
2+ concentra-
tion [32]. For instance, the activity of endothelial nitric
oxide synthase (eNOS) in producing nitric oxide in
endothelial cells absolutely requires CaM [33] and it
a p p e a r st oa l s or e q u i r eC a
2+ to sustain elevated level of
activity [34].
Nitric oxide plays a critical role in the endothelial cell
proliferation, migration, and tube formation, as well as
increased vascular permeability, hypotension, and angio-
genesis in vivo [35,36]. VEGF- and histamine-induced
microvascular hyperpermeability are both mediated by a
signalling cascade triggered by receptor binding and
transduced by a serial activation of intracellular
enzymes, including PLC, eNOS, soluble guanylate
cyclase (sGC), and protein kinase G (PKG). Subse-
quently, the VEGF-activated NO-PKG pathway was
linked to ERK1/2-mediated proliferation of cultured
endothelial cells via phosphorylation and activation of
the upstream p42/44 MAPK cascade component RAF
by PKG [37].
Thrombin, VEGF and Histamine mediated MLC activation
MLC of myosin II plays a critical role in controlling
actomyosin contractility in both smooth muscle and
nonmuscle cells [38-40]. MLC phosphorylation is regu-
lated by the balance of two enzymatic activities, i.e.,
MLCK and myosin phosphatase (MYCP). MLCK is
regulated by Ca
2+/calmodulin and is believed to be a
major kinase in both smooth muscle and nonmuscle
cells. In addition, Rho-kinase (ROCK) can directly phos-
phorylate MLC in vitro [41]. MYCP is a holoenzyme
composed of three subunits: a catalytic subunit of 38
kDa that was identified as protein phosphatase 1 (PP1)
catalytic subunit δ-isoform (PP1Cδ) [42] and two nonca-
talytic subunits of 21 and 110-130 kDa [43,44]. The lar-
ger one, called myosin phosphatase targeting subunit 1
(MYPT1), binds to the catalytic subunit and targets it to
MLC, providing substrate specificity [45]. ROCK and
PKC have been proposed to mediate the inhibition of
smooth muscle MYCP, leading to increased MLC phos-
phorylation in response to various agonists.
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in chicken MYPT1) by ROCK induces inhibition of
MYCP activity [46]. Some experimental findings suggest
that CPI-17, a soluble globular protein, is involved in
PKC-dependent inhibition of MYCP and it has thus
been considered as a specific inhibitor for MYCP [47].
Detail description of signaling cascades used in this
model was provided the Additional File 3.
Results and Discussion
Model validation with experimental studies of the
regulation of MLC activation, calcium release, and Rho
activation by thrombin
Our simulation model was first validated by determining
whether the simulation results were consistent with
experimental observations of MLC activation and cal-
cium release by the single mediator thrombin. Throm-
bin-mediated processes were investigated
computationally by zeroing out the initial concentration
of VEGF and histamine. It has been observed that MLC
activation increases from low initial levels to 39% ± 2%,
66% ± 10, 68% ± 13%, 64% ± 13%, and 67 ± 9% of the
MLC population at 30s, 60s, 2.5 min, 15 min, and 30
min after thrombin stimulation, respectively, which sub-
sequently drops to 48% at 60 min [48]. The amplitude
of MLC activation has been found to correlate linearly
with the strength of endothelial cell contraction [49,50].
As illustrated in Figure 2 (Left), our simulated time-
dependent MLC activation levels are in fair agreement
with this observation (the simulation results for the first
20 min are also shown in Additional File 1, Figure S4).
Our simulations showed that the amplitude of MLC
activation reaches two peaks, the first at ~2.5 min and
the main peak at ~30 min, which is compared to the
observation that the levels of active MLC levels at 2.5
min and 30 min are higher than those at 15 min and 60
min [48]. Our analysis suggested that these two peaks
arise primarily from the Ca
2+-dependent and Rho
GTPase/ROCK-dependent mechanisms, respectively, as
described below.
Elevation in cytosolic Ca
2+ concentration ([51]) is a
common initial response of endothelial cells to various
changes such as the exposure to hormonal and inflam-
matory stimuli and variation of physical conditions [52].
Jeng et al. [53] have shown that the binding of thrombin
and PAR-1 induces rapid calcium mobilization and
increase of [Ca
2+]i, with [Ca
2+]i peaking at 30-40 s fol-
lowed by a rapid drop. The simulated calcium release
profile in Figure 2 (Right) exhibits a peak concentration
at 38 s followed by a rapid decay, consistent with Jeng
et al’s experiment results. The increased intracellular
Ca
2+ influx is expected to enhance the binding of Ca
2+
to CaM, which subsequently activates MLCK to phos-
phorylate the MLC of myosin II. To evaluate which sig-
nalling event is primarily responsible for the large
transient increase in the level of MLC activation (the
first peak at ~2.5 min in the left Figure 2), we systemati-
cally varied the strength of protein-protein interactions
upstream of MLC. As shown in Additional File 1, Figure
S5, the first peak disappears when the Ca
2+-dependent
MLC activation (Reaction 73-86) was switched off, while
that peak remains largely intact when the ROCK-depen-
dent MLC activation and CPI-17-MYPT interactions
were switched off (Reactions 57-58, 63-70, 99-102),
Therefore, our analysis suggests that this Ca
2+-depen-
dent mechanism was primarily responsible for the large
transient increase of the levels of MLC activation.
Thrombin induces a prolonged increase of endothelial
permeability lasting for 1-1.5 hr. This prolonged ele-
vated permeability is attributed to the activation of the
small Rho GTPase and Rho kinase [54,55]. It has been
found that Rho GTPase activation can be observed after
2 min and the elevated activation is maintained up to 60
min after thrombin stimulation, and the time course of
Rho GTPase activation correlates well with the time
course of MLC activation increase by experiment
Figure 2 Simulated time course and experimental data of thrombin-mediated MLC activation (left) and calcium release (right).
Histamine and VEGF level set as zero values. refers to experimentally measured MLC activation at 2.5 min (68% ± 13%), 15 min (64% ± 13%), 30
min (67% ± 9%) and 60 min (48% ± 9%) (Ref 48).
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Additional File 1, Figure S6 is consistent with this obser-
vation, which shows that the simulated Rho GTPase
activation was maintained for 60 min. Rho GTPase acti-
vation induces MLC activation via both direct and indir-
ect routes. Rho GTPase and ROCK directly activate
MLC to subsequently induce the contraction of the
non-muscle cell systems [41,56]. In the indirect route,
ROCK inhibits myosin phosphatase activity by phos-
phorylating the myosin binding subunit (MBS) of myo-
sin phosphatase [46], which increases the activation
level of MLC, actomyosin interaction, stress fiber forma-
tion, and subsequent endothelial permeability. We stu-
died whether these direct and indirect Rho GTPase
-dependent mechanisms are primarily responsible for
the sustained levels of MLC activation (the main peak at
~30 min in the left Figure 2) by systematically varying
the protein-protein interactions upstream of MLC. As
shown in Additional File 1, Figure S7, this peak remains
largely intact when the Ca
2+ -dependent MLC activation
and P-CPI-17-MYPT interaction (Reaction 57-58, 71-76)
were switched off, but disappeared when the ROCK-
dependent MLC activation (Reactions 63-70, 99-102)
were switched off. Therefore, our analysis suggests that
both the direct and indirect Rho GTPase -dependent
mechanisms play an important role for the sustained
levels of MLC activation.
Model validation with experimental studies of MLC
activation and ERK activation by VEGF
Our simulation model was also validated by determining
whether the simulation results are consistent with
experimentally observed regulation of MLC activation as
well as ERK and MLCK activation by another mediator
VEGF. These VEGF-mediated processes were simulated
by using our model with thrombin and histamine
switched off by setting their initial concentrations to
zero values. It has been reported that injection of VEGF
induces vascular leakage in 5 min, and the leakage peaks
in 15-20 min and then diminishes after 30 min [57]. As
shown in Figure 3 (Left), the simulated duration of
MLC activation is about 30 min with the first peak at
2.5 min and the main peak at 15 min. The 15 min time
range of the main peak of MLC activation is consistent
with the reported 15-20 min time range for VEGF-
induced vascular leakage to reach its peak [57]. While
we have not found an experimental finding to support
the true existence of the first peak exhibited by our
simulation, it is noted that the time of the first peak
matches the experimentally determined on-set time of
VEGF-induced vascular leakage [57]. As described in the
previous section, the first peak of MLC activation at
~2.5 min in Figure 3 (Left) was induced mainly by Ca
2
+-dependent mechanism. We further investigate which
signalling event is primarily responsible for the main
peak at ~15 min. As shown in Additional File 1, Figure
S8. We found that this peak remained when NO-depen-
dent MLC activation was switch off (Reactions 179-185)
but disappeared when Ras-Raf-ERK-dependent MLC
activation was switch off (Reactions 152-163). This sug-
gests that the main peak is induced by Ras-dependent
ERK activation. As shown in Figure 3 (Right), the simu-
lated ERK activation peaks at about 7 min and decays
within 25 min, which is consistent with the observation
that the amount of phosphorylated ERK-1/2 reaches
maximum value at 5-10 min after administration of
VEGF and decreases back to the control level 30 min
afterward [58].
Model validation with experimental studies of MLC
activation by histamine
The model was further validated by determining
whether the simulation results are consistent with
experimentally observed regulation of MLC activation
Figure 3 Simulated time course and experimental result of VEGF-mediated MLC activation (left) and ERK activation (right). Thrombin
and histamine level set at zero values. The shaded area in the left figure indicates the time range in which VEGF-induced vascular leakage
reaches its peak in experimental studies (Ref 57). The shaded area in the right figure indicates the time range in which the amount of ERK-1/2
activation reaches maximum value after VEGF administration (Ref 58). The VEGF concentrations were set as 0.02 μM.
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mine-mediated process was simulated by using our
model with thrombin and VEGF switched off by setting
their initial concentrations to zero values. The simula-
tion results in Additional File 1, Figure S9 indicated that
histamine causes a transient increase of MLC activation
that peaked at 2.5 min, which is consistent with the
experimental finding that histamine induces a transient
endothelial permeability peaked at 2-5 min [7]. Further
investigation showed that this peak is primarily induced
by Ca
2+-dependent mechanism and the contribution
from the NO-dependent ERK activation path is very
small, as shown in Additional File 1, Figure S10 by
switching off each individual path. Moreover, the contri-
bution from the NO-dependent ERK activation path is
much weaker compared with Ras-dependent ERK activa-
tion and MLC activation by the individual mediator
VEGF.
Comparison of the simulated thrombin-mediated IP3 and
Ca
2+ release with that of an existing model
The thrombin signalling cascade of our model is very
similar to that of Maeda et al. that has been developed
a computational model of thrombin-regulated ROCK
pathway [18]. Hence, it is appropriate to compare the
simulation results of our model with Maeda’sm o d e l .I n
their studies, they measured and simulated thrombin-
mediated IP3 and Ca
2+ release. We therefore compared
our simulated IP3 and Ca
2+ release with their results. As
shown in Figure 4, our simulation showed essentially the
same transit IP3 release and Ca
2+ release patterns as
those presented in Maeda’s studies.
Simulation of the effects of thrombin receptor PAR-1
over-expression on thrombin-mediated MLC activation
PAR-1 is the major thrombin-activated receptor
involved in platelet aggregation, endothelial
permeability, and tumor cell migration. Activated PAR-1
is coupled via several members of the heterotrimeric G-
proteins, Ga12/13 and Gaq, to transduce a substantial
network of signalling pathways [26]. It has been
reported that during atherogenesis, PAR-1 expression is
enhanced in regions of inflammation associated with
macrophage influx, smooth muscle cell proliferation,
and an increase in mesenchymal-like intimal cells [59].
It is of interest to quantitatively evaluate the effects of
PAR-1 elevation on thrombin-mediated MLC activation.
We further used our model to simulate thrombin
mediated MLC activation at different PAR-1 levels with
VEGF and histamine switched off [60]. Our simulation
results, in Figure 5, showed that PAR-1 at elevated levels
significantly increases the amplitude of MLC activation
and reduces the time for MLC activation to reach the
main peak. There is a direct correlation between the
level of PAR-1 expression and the degree of invasiveness
of breast carcinoma cell lines [61], in which endothelial
permeability is one of the prerequisites for cancer inva-
siveness as it facilitates cell transmigration and plasma
accumulation in the matrix to support new vessel for-
mation [60]. Therefore, this experiment indicated that
PAR-1 over-expression leads to enhanced endothelial
hyper-permeability, and our simulation results are in
good agreement with this experimental finding.
Simulation of the effects of Rho GTPase and ROCK over-
expression on thrombin-mediated MLC activation
Rho GTPase and ROCK in endothelial cells have been
found to be elevated in hypoxia [62]. Over-expression of
dominant activated Rho GTPase/ROCK in NIH3T3 cells
results in an increase of MLC activation [46]. Over-
expressed ROCK in human brain microvascular
endothelial cells has been found to induce endothelial
permeability and to significantly increase the
Figure 4 Comparison of simulation result of Ca
2+ and IP3 in
our model and Maeda’s model.
Figure 5 MLC activation at different PAR-1 concentrations.
Thrombin level set at 0.05 μM with histamine and VEGF level at
zero value. The physiological concentration range of PAR-1 is 0.002 -
0.02 μM.
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human brain microvascular endothelial cells [63]. The
effects of elevated Rho GTPase and ROCK on throm-
bin-mediated MLC activation were quantitatively evalu-
ated by using our model with VEGF and histamine
switched off. As shown in Figure 6, an increased ROCK
level with Rho GTPase at control level significantly
enhanced the amplitude of activation of MLC in a dose-
dependent manner. When ROCK and Rho GTPase
levels were simultaneously elevated, the amplitude of
MLC activation was significantly increased and the time
to reach the activation peak was reduced. Rho GTPase
and ROCK are abundant in lymph nodes with metasta-
sis, and the ability to enter either blood or lymphatic
vasculature is necessary for tumor cells to metastasize to
distant sites [64]. Furthermore, Rho GTPase and ROCK
reportedly are required in both endothelial and migrat-
ing cells for them to cross the vascular endothelium
[65,66]. Thus, by quantifying the effect of Rho GTPase/
ROCK, we can gain more insight into the mechanism of
sustained MLC activation, which may aid the search for
and evaluation of new therapeutic strategies for the pre-
vention and treatment of endothelial hyper-permeability
and cancer metastasis-related diseases.
Simulation of effects of VEGF and VEGFR2 over-
expression on VEGF-mediated MLC activation
VEGFR2 is recognized as the principal mediator of phy-
siological and pathological effects of VEGF on endothe-
lial cells, which include proliferation, migration, survival,
and permeability [67]. The expression of VEGF and
VEGFR2 in endothelial cells has been found to be ele-
vated in oxidative stress [68], type 1 leprosy reaction
[69], and during diabetes to induce microvascular com-
plications, especially diabetic retinopathy [70]. Over-
expression of VEGF and VEGFR2 has been shown to
correlate with increased risk of metastatic disease and
overall poor prognosis in different carcinomas [71].
Apart from their primary functions in angiogenesis, the
roles of VEGF and VEGFR2 in metastasis likely involve
the regulation of endothelial permeability to facilitate
cell transmigration and plasma accumulation in the
matrix in support of new vessel formation [72]. The
effects of VEGF and VEGFR2 over-expression on
VEGF-mediated MLC activation were quantitatively
evaluated by using our model with thrombin and hista-
mine switched off.
As shown in Figure 7, the increased amount of
VEGFR2 with VEGF at control level significantly
enhanced MLC activation. For instance, the small
increase of VEGFR2 concentration from 0.010 to 0.012
μM increased the amplitude of the main peak of MLC
activation by 15%, suggesting that MLC activation was
very sensitive to VEGFR2 concentration. When VEGF
and VGEFR2 levels were simultaneously increased, the
amplitude of MLC activation was further increased by a
significant amount with respect to that when only
VEGFR2 was over-expressed. This is consistent with the
observed correlation of VEGF and VEGFR2 over-expres-
sion with increased risk of metastatic disease and overall
poor prognosis in different carcinomas [71].
Simulation of synergistic activation of MLC by thrombin
and histamine
It has been reported that combination of low concentra-
tions of stimuli of thrombin and histamine induces
more significantly enhanced endothelial permeability
than the simple sum of the permeability change induced
by each mediator alone [73]. The effect of the combina-
tion of low concentrations of thrombin and histamine
on MLC activation was explored by using our model
with the third mediator VEGF switched off. As illu-
strated in Figure 8, from 10 min to 50 min after stimu-
lation with combination of 0.0015 μM thrombin and
0.0050 μM histamine, the amplitude of MLC activation
reached levels of >65%, which is greater than the simple
sum of <35% and <22% when only one individual
Figure 6 MLC activation at different Rho GTPase (A) and ROCK
(B) concentrations. Thrombin level set at 0.05 μM with histamine
and VEGF level at zero value. The physiological concentration range
of ROCK is 0.06 - 0.3 μM.
Figure 7 MLC activation at different VEGF(V) and VEGFR2 (VR)
concentrations. Thrombin and histamine levels set at zero values.
The physiological concentration range of VEGFR is 0.012-0.072 μM.
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switched on. Therefore, our simulation results indicated
a synergistic effect of histamine and thrombin, in agree-
ment with observations [73]. Moreover, the levels of
MLC activation induced by these low concentrations of
thrombin and histamine are comparable to (higher than)
those induced by individual mediator thrombin and his-
tamine at concentrations of 0.0500 μM and 0.005 μM,
respectively, which suggests that the synergistic effect is
at a substantial level.
T h el e v e lo fs y n e r g i s t i ce f f e c tc a nb em o r ec l e a r l y
revealed by the comparison of the areas under the
thrombin and histamine induced MLC activation curve
with those of thrombin-induced and histamine-induced
MLC activation curves at different 10 min time intervals
in Figure 8, which are provided in Table 1. In particular,
the level of synergistic effect can be reflected by the dif-
ference between the area under the thrombin and hista-
m i n ei n d u c e dc u r v ea n dt h es i m p l es u mo ft h ea r e a s
under the thrombin-induced and histamine-induced
curves, with positive values corresponding to synergistic
effect (better than simple sum of thrombin-induced and
histamine-induced activation). From Table 1, the largest
synergistic effect occurs in the 10-20 min, 20-30 min
and 30-40 min time ranges with net area gain of 1.3, 1.8
and 1.5 (corresponding to an average of 13%, 18% and
15% more amount of activated MLC with respect to
that of simple sum of thrombin-induced and histamine-
induced activation).
As shown in Figure 8, the synergistic effect at low
concentrations of thrombin and histamine only occur
during the time range from 10 min to 50 min. Before
and after this time range, the level of MLC activation by
thrombin + histamine is less than the simple sum of
that by thrombin and histamine alone. The less than
additive effect during the first 10 min is primarily due
to the time-dependent behavior of MLC activation by
the Ca
2+-dependent signalling cascade. The transient
MLC activation curve by the Ca
2+-dependent cascade is
largely the same for the thrombin, histamine, and
thrombin + histamine mediated processes (Additional
File 1, Figure S11, S12 and S13, solid line). It is thus not
d i f f i c u l tt ou n d e r s t a n dt h a tt h es i m p l es u mo ft h el e v e l
of MLC activation by thrombin and histamine alone is
superficially larger than that by thrombin + histamine.
The less than additive effect after 50 min is primarily
due to the variation of time-dependent behavior of MLC
activation by the ROCK-dependent signalling cascade.
The level of MLC activation slowly rises to significant
levels without decay in the presence of thrombin alone
for up to 100 min (Additional File 1, Figure S11, dotted
and dash-dotted line). On the other hand, the MLC acti-
vation level rises slowly to moderate levels without
decay in the presence of histamine alone (Additional
File 1, Figure S12). In contrast, the MLC activation level
quickly rises to high levels and rapidly decays to low
levels after 50 min in the presence of thrombin + hista-
mine, the signalling strength thus becomes less than
additive after 50 min (Additional File 1, Figure S13,
dash-dotted line ).
The underling mechanism of the significant synergistic
effect during 10-50 min time period can be elucidated
from the perspective of network regulation. MLC
Figure 8 MLC activation induced by combination of thrombin
and histamine stimuli. The solid, long dashed, and dot line
corresponds to the activation by thrombin and histamine with VEGF
level set at zero value, by thrombin with histamine and VEGF level
set at zero values, and by histamine with thrombin and VEGF level
set at zero value respectively.
Table 1 Comparison of the areas with respect to different time ranges in Figure 8
MLC activation curve Area under MLC activation curve with respect to different time range
(time unit:min)
0-10 10-20 20-30 30-40 40-50 50-60 60-70 70-80
Curve 1:Histamine + Thrombin induced activation 5.9 7.8 7.6 6.9 6.1 5.2 4.7 4.0
Curve 2:Histamine-mediated activation 4.3 3.1 2.6 2.3 2.0 1.6 1.4 1.3
Curve 3:Thrombin-mediated activation 4.4 3.4 3.2 3.1 3.1 3.0 3.0 2.9
Simple sum of curve 2 and 3 8.7 6.5 5.8 5.4 5.0 4.7 4.5 4.3
Area difference between curve 1 and simple sum of curve 2 and 3 -2.8 1.3 1.8 1.5 1.1 0.6 0.2 -0.3
Comparison of the areas under the thrombin and histamine induced MLC activation curve with those of thrombin-induced and histamine-induced MLC activation
curves with respect to different time ranges in Figure 8.
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Page 8 of 15activation is regulated by at least four signalling cascades
Ca
2+-dependent, CPI-17-dependent, NO-dependent, and
ROCK-dependent cascades (Figure 1). As shown in
Additional File 1, Figure S11, S12, and S13, The MLC
activation curve induced by the Ca
2+-dependent cascade
is roughly the same for the thrombin, histamine and
thrombin + histamine mediated processes. The level of
MLC activation induced by the CPI-17-dependent, NO-
dependent cascade in the presence of thrombin + hista-
mine is close to the simple sum of that in the presence
of thrombin and histamine alone. While the MLC acti-
vation induced by the ROCK-dependent cascade in the
presence of thrombin + histamine is at significantly
higher levels and shows more transient pattern than
t h a ti nt h ep r e s e n c eo ft h r o m b i na n dh i s t a m i n ea l o n e .
These differences in signalling behavior lead to synergis-
tic effect within 10 min to 50 min time range.
The different signalling behavior of the Rho-ROCK sig-
nalling stimulated by different mediators or mediator com-
binations primarily arises from the dynamics of ROCK
activation [74]. The kinase activity of ROCK is off when
ROCK is intra-molecularly folded. ROCK can be activated
only after it is unfolded by the binding of Rho GTPase to
its Rho-binding domain to disrupt the auto-inhibitory
interaction, which subsequently allows such proteins as
Rho GTPase and PKG to activate ROCK at phosphoryla-
tion site. Hence, in the presence of thrombin + histamine,
thrombin-activated Rho GTPase unfolds ROCK to allow
histamine-activated PKG to activate ROCK thereby enhan-
cing the level of ROCK activation in combination with
thrombin-mediated Rho GTPase activation of ROCK.
When stimulated by histamine or VEGF alone, ROCK is in
the inactive state and does not contribute to MLC activa-
tion. When stimulated by thrombin alone, ROCK is acti-
vated only by Rho GTPase without the contribution from
PKG, leading to a slower increase and lower peak strength
of MLC activation than that in the presence of thrombin +
histamine. Such an integrated communication network is
expected to enable fine tuning of the strength and duration
of MLC activation, thereby enabling fine regulation of phy-
siological responses, including synergistic or more complex
effects. Network models have suggested that partial inhibi-
tion of a surprisingly small number of targets can be more
efficient than the complete inhibition of a single target
[75]. Experimental and simulation studies of synergistic
effects of thrombin and histamine on endothelial mono-
layer permeability may provide useful information for
developing multi-target drugs against endothelial perme-
ability and related diseases [75].
Prediction of the collective regulation of MLC activation
by thrombin and VEGF
Our simulation model was further used to study the col-
lective regulation of MLC activation by thrombin and
VEGF, with a particular focus on whether or not throm-
bin and VEGF synergistically activate MLC in certain
time ranges. Systemic activation of blood coagulation is
often present in cancer patients, and thrombin gener-
ated during thrombosis can augment malignant pheno-
types by activating tumor cell adhesion to platelets and
endothelial cells, enhancing tumor cell growth and
metastasis, and stimulating tumor cell angiogenesis [1].
Moreover, thrombin promotes VEGF secretion and pla-
telet activation, thus causing a mutual stimulation
between endothelial cells and cancer cells [76,77].
Therefore, the collective effect of thrombin and VEGF
on MLC activation and subsequently endothelial hyper-
permability may have substantial influence on the tumor
growth and metastasis process in cancer patients with
blood coagulation near and at the tumor sites [78].
As shown in Figure 9, from 15 min to 30 min after
stimulation with combination of 0.002 μM thrombin
and 0.010 μM VEGF, the amplitude of MLC activation
reached levels of >62%, which is greater than the simple
sum of <32% and <28% when only one individual med-
iator, thrombin and VEGF, respectively, was switched
on. Therefore, our simulation results indicated a syner-
gistic effect of histamine and VEGF on MLC activation.
The level of synergistic effect can be reflected by the dif-
ference between the area under the thrombin and VEGF
induced curve and the simple sum of the areas under
the thrombin-induced and VEGF-induced curves in Fig-
ure 9, which are shown in Table 2. From Table 2, the
largest synergistic effect occurs in the 20-30 min time
range with net area gain of 1.8 corresponding to an
average of 18% more amount of activated MLC with
respect to simple sum of thrombin-induced and VEGF-
induced activation. The high level MLC activation by
Figure 9 MLC activation induced by the combination of
thrombin and VEGF stimuli. The solid, long dashed, and dot line
corresponds to the activation by thrombin and VEGF with histamine
level set at zero value, by thrombin with histamine and VEGF level
set at zero value, and by VEGF with thrombin and histamine level
set at zero values.
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Page 9 of 15thrombin and VEGF likely has significant impact on the
promotion of cancer metastasis in the cancer patients
with blood coagulation near and at the tumor sites.
These patients may be more effectively treated by com-
binations of drugs targeting the VEGF and thrombin
signalling pathways [78].
Prediction of the effect of CPI-17 over-expression on MLC
activation in the presence of lower concentration of
thrombin, histamine and VEGF
CPI-17 inhibits MYCP to hinder its dephosphorylation
of MLC, leading to increased MLC activation [79].
Altered CPI-17 level is associated with smooth muscle-
related diseases, such as intestinal bowel disease [80],
asthma [81], pulmonary hypertension [82] and diabetic
dysfunction of smooth muscle [83]. It is of interest to
evaluate the effect of CPI-17 over-expression on MLC
activation, particularly at lower level of thrombin, hista-
mine and VEGF. In this work, CPI-17 over-expression
was simulated by 5-fold increase of its level from 0.08
μMt o0 . 4μM [84]. Each of the thrombin-, histamine-
and VEGF- mediated processes was simulated by setting
the concentration of thrombin, histamine and VEGF set
at lower value of 0.0015 μM, 0.005 μM and 0.01 μM
respectively with the other two mediators switched off
by setting their initial concentrations to zero values. As
shown in Figure 10, CPI-17 over-expression significantly
strengthened and prolonged MLC activation to the
levels higher than those at normal CPI-17 level and nor-
mal concentration of thrombin, histamine and VEGF
respectively [85].
Conclusion
Thrombin, VEGF, and histamine are hallmarks of
endothelial hyper-permeability, which perform their reg-
ulatory roles individually and collectively under different
disease conditions, and with different dynamic profiles.
Thrombin and VEGF can increase microvascular perme-
ability ~50,000 times more potently than histamine [86].
Thrombin, VEGF, and histamine induce prolonged (1-
1.5 hr), intermediate (15-20 min) and transient (~5 min)
increases of endothelial permeability, respectively. An
integrated simulation model that includes the signalling
of all these hallmark mediators enables more compre-
hensive analysis of the signalling processes involved in
different disease processes and regulated by different
combinations of these mediators.
Based on published models of relevant signalling, we
developed an integrated mathematical model including
the signalling pathways of all three of these mediators.
Simulation results from our model were consistent with
available experimental data of signalling mediated by
both individual mediators and combinations of two
mediators, and could be used to interpret the sustained
and transient phases of MLC activation. Our model was
able to predict the effects of altered pathway compo-
nents and synergistic combination of multiple mediators,
some of which are consistent with experimental findings
[73]. Similar to the published models of other pathways,
our model can potentially be used to identify important
disease genes through sensitivity analysis of signalling
components [87]. Our model may also be extended to
Table 2 Comparison of the areas with respect to different time ranges in Figure 9
MLC activation curve Area under MLC activation curve with respect to different time range
(time unit:min)
0-10 10-20 20-30 30-40 40-50 50-60 60-70 70-80
Curve 1:Thrombin + VEGF induced activation 5.0 6.2 6.7 5.1 3.4 2.4 1.9 1.4
Curve 2:VEGF-mediated activation 4.1 3.5 2.9 3.2 3.3 3.4 3.4 3.1
Curve 3:Thrombin-mediated activation 4.0 2.6 2.0 1.1 0.05 0.5 0.4 0.3
Simple sum of curve 2 and 3 8.1 6.1 4.9 4.3 3.35 3.9 3.8 3.4
Area difference between curve 1 and simple sum of curve 2 and 3 -3.1 0.1 1.8 0.7 0.05 -1.5 -1.9 -2.0
Comparison of the areas under the thrombin and VEGF induced MLC activation curve with those of thrombin-induced and VEGF-induced MLC activation curves
with respect to different time ranges in Figure 9.
Figure 10 Prediction of the effect of CPI-17 over-expression on
MLC activation at low concentration of stimuli. Solid and doted
lines correspond to the activation by default (CPI-17 = 0.08 μM) and
elevated (CPI-17 = 0.4 μM) concentration of CPI-17. Blue line refers
to thrombin stimuli, green line refers to histamine stimuli, and red
line refers to VEGF stimuli respectively.
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gation of the effects of different mediators, cascades, and
cross-talk on endothelial permeability and related
diseases.
Methods
Model Development
One of the most commonly used approaches to model
biological systems is that of ODEs. In general, a differ-
ential equation can be used to describe the chemical
reaction rate that depends on the change of participat-
ing species over time. The temporal dynamic behavior
of molecular species in the biological signalling pathway
network can be captured by a set of coupled ODEs. Our
pathway model is illustrated in Figure 1. Thrombin,
VEGF and histamine induced MLC activation, as well as
Ca
2+-dependent and ROCK-dependent activation of
MLC, were included in the model. The constituent
molecular interactions, their kinetic constants and mole-
cular concentrations are described in detail in Addi-
tional File 2. The ODEs for these interactions were
derived based on mass-action laws with interaction rate
constants defined by the forward and reverse rate con-
stants Kf and Kb or turnover number Kcat for enzy-
m a t i cr e a c t i o n sd e r i v e df r o mp u b l i s h e dm o d e l s[ 8 8 , 8 9 ]
and other literature. Our simulation model contains 200
equations and interactions and 185 distinct molecular
species, characterized by 319 kinetic parameters and 48
initial molecular concentrations. These ODEs were then
solved by using the Dormand-Prince pair based Ode45
solver of Matlab with the absolute tolerance of 1.0E-6
and relative tolerance 0.0010. A Systems Biology
Markup Language (SBML) version of our model is pro-
vided at http://bidd.nus.edu.sg/group/Supplement.htm,
and uploaded into the BioModels [90] and KDBI [91]
databases (Additional File 4).
Collection and estimation of kinetic parameters
The types of parameters used in our model are para-
meters governing protein-protein interactions and cata-
lytic activities. The published simulation studies have
found that most parameters are robust and moderate
changes do not significantly alter the overall pathway
behavior [15,16,18]. Apart from the use of the para-
meters of the published simulation models, additional
parameters were obtained from the literature based on
the widely used assumption that parameters measured
in vitro and in some cell lines are generally applicable in
most cases. For those protein-protein interactions with-
out available parameters, their parameters were puta-
tively estimated from the known parameters of the
relevant interacting domain profile pairs [92,93] or other
interacting protein pairs of similar sequences. As a
biological network is believed to be robust, and protein-
protein binding interactions for proteins in similar
families that mediate similar types of biochemical reac-
tions (such as Ras and Rho) often differ within a 10-fold
range, the values of kinetic parameters obtained from
previous models were optimized within this range.
The parameters of the protein-pairs not available from
previous models were obtained by the following proce-
dure: The first step in finding the parameters of a speci-
fic protein-pair is to search protein-pairs that are both
with available parameters and with each individual pro-
tein similar in sequence with the respective protein of
the studied protein-pair. If one or more such protein-
pairs are found, then the average values of the para-
meters of these protein-pairs are used as the initial para-
meters of the studied protein-pair, which are further
optimized in ± 10-fold range with respect to experimen-
tal data. For instance, the parameters for the Rho activa-
tion cycle were obtained from the Ras activation cycle
and were further optimized within a 10-fold range. The
cycle of optimization and validation was repeated in
order to obtain simulated results that agreed well with
known experimental trends. If no such protein-pair is
found, we proceed to the second step to search protein-
pairs that are both with available parameters and with
each individual protein belonging to the same domain
family of the respective protein of the studied protein-
pair. If one or more such protein-pairs are found, then
the average values of the parameters of these protein-
pairs are used as the initial parameters of the studied
protein-pair, which are further optimized in ± 10-fold
range with respect to experimental data.
The parameters of RhoGAP and PKC related protein-
pairs were determined by the first and second step. The
parameters of 14 protein-pairs could not be determined
by the first and second step due to lack of experimental
data and relevant protein-pairs with known parameters.
These parameters were determined by using the trust
regions algorithm [94] to fit the simulation results to
the experimental data of RAS, ERK, MYPT and CPI-17
activation curves [95-97]. Additional File 1, Figure S14
shows the fitting curve against experimental RAS activa-
tion data. The level of fitting is based on the least-
squares method and the fitting process proceeds in
iterations until the R-square value is >0.6[98]. In each
iteration, the parameter values derived from the pre-
vious iteration were used as the starting parameters for
further optimization.
Model Optimization, Validation and Parameter Sensitivity
Analysis
Mathematical models developed by ‘one-set-fits-all’ gen-
eric parameters need not reproduce quantitative
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the behavior or trend for specific systems. For instance,
a mathematical model developed for a biological path-
way from parameters obtained experimentally from one
cell type can behave slightly different in another cell
types. Differences in model behavior between cell types
can be due to the presence or absence of crosstalk (i.e.,
differences in model topology) and variation in effective
values of kinetic parameters. Hence, in this study, we
developed a generic model of the thrombin-, VEGF-,
and histamine-MLC signalling pathway to investigate
the role of these three main mediators in regulating
MLC activation. The simulated results are represented
as trajectories of concentrations of chemical species
with respect to time that are validated against available
experimental data. If the trend or dynamic behavior of a
particular reactant or product behaves in such a way
that is consistent with the experimental data, then the
model is said to be reasonable and can be used to ana-
lyze and predict unknown biological phenomena within
some difficulty to define range of conditions. If the
simulation results are not in agreement with known
experimental facts, then the model has to be revisited
to examine possible errors, such as incorrect interaction
kinetics or values of kinetic parameters. Optimized
parameters obtained from previous mathematical mod-
els are not necessarily optimized in a new study as the
scope of these models can be different. The cycle of
optimization and validation are repeated in order to
obtain simulated results that agree well with known
experimental trends.
The sensitivity of the simulation results with respect
to the optimized and other parameters need to be sys-
tematically analyzed to determine if the model is suffi-
ciently robust to be able to analyze and predict the true
dynamic behavior of biological networks without the
artifact of parameters. Differential analysis of parameter
sensitivity, also referred to as the direct method, was uti-
lized to compute the time-dependent sensitivities of all
the species states with respect to each parameter values
in the model [99]. Complex-step derivative approxima-
tion [100] was used to calculate numerical derivatives of
the reactions in the model to achieve near analytical
accuracy, robustness and easy implementation. We used
sensitivity analysis function of Matlab to conduct sensi-
tivity analysis. The sensitivity value of ppMLC with
respect to all parameters in the model was provided in
Additional File 5 and Additional File 1, Figure S15. As
shown in Additional File 1, Figure S15, only 14 (4%)
kinetic parameters including CPI-17, PKC and ROCK
related reactions showed some sensitivity in affecting
t h eo u t p u t .T h em a j o r i t yo ft h ep a r a m e t e r sa r ei n s e n s i -
tive in affecting the output. Thus, our model can be
considered as sufficiently robust.
Additional material
Additional file 1: Supplementary Figures. Detailed pathway map
(Figure S1-S3); Simulated time course and experimental data(Figure S4,
S6, S9);Simulated time course of MLC activation in terms of different
components (Figure S5, S7, S8, S10-S13); Fit to experimental data for Ras
activation (Figure S14); Parameter sensitivity analysis (Figure S15).
Additional file 2: Supplementary Table. Chemical reactions and
related kinetic parameters used in this model.
Additional file 3: Supplementary Model Description. Detail
description of signaling cascades used in this model.
Additional file 4: SBML file for the model. A Systems Biology Markup
Language (SBML) version of our model was provided in Additional File 5.
Additional file 5: Sensitivity analysis data. The sensitivity value of
ppMLC with respect to all parameters in the model was provided in
Additional File 4.
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